These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 6149804)

  • 1. The 12th J. A. F. Stevenson memorial lecture. Aging, Alzheimer's disease, and the cholinergic system.
    McGeer PL
    Can J Physiol Pharmacol; 1984 Jul; 62(7):741-54. PubMed ID: 6149804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurotransmitter anomalies in Alzheimer's disease].
    Berger B
    Rev Neurol (Paris); 1984; 140(10):539-52. PubMed ID: 6150545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography and the possible origins of cytopathology in Alzheimer's disease.
    McGeer PL; McGeer EG; Kamo H; Wong K
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):501-18. PubMed ID: 3541048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.
    Chan-Palay V
    J Comp Neurol; 1988 Jul; 273(4):543-57. PubMed ID: 2463283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function.
    Gibbs RB
    Exp Neurol; 1998 Jun; 151(2):289-302. PubMed ID: 9628764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylcholine, aging, and Alzheimer's disease.
    Muir JL
    Pharmacol Biochem Behav; 1997 Apr; 56(4):687-96. PubMed ID: 9130295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disturbances in neurotransmission processes in aging and age-related diseases.
    Ossowska K
    Pol J Pharmacol; 1993; 45(2):109-31. PubMed ID: 8401765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. III. The basal forebrain compared with other subcortical areas.
    Arendt T; Brückner MK; Bigl V; Marcova L
    J Comp Neurol; 1995 Jan; 351(2):223-46. PubMed ID: 7699112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The morphological basis of dementia in Parkinson's disease.
    Ball MJ
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):180-4. PubMed ID: 6713315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain.
    McGeer PL; McGeer EG; Suzuki J; Dolman CE; Nagai T
    Neurology; 1984 Jun; 34(6):741-5. PubMed ID: 6539435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cholinergic system in Alzheimer's disease.
    Kása P; Rakonczay Z; Gulya K
    Prog Neurobiol; 1997 Aug; 52(6):511-35. PubMed ID: 9316159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal communication breakdown in neurotransmitter systems in Alzheimer's and Parkinson's dementias.
    Chan-Palay V
    J Neurocytol; 1990 Oct; 19(5):802-6. PubMed ID: 1706418
    [No Abstract]   [Full Text] [Related]  

  • 13. Do raised brain aluminium levels in Alzheimer's dementia contribute to cholinergic neuronal deficits?
    King RG
    Med Hypotheses; 1984 Jul; 14(3):301-6. PubMed ID: 6472159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of corticotropin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei--potential implication for arousal and attention.
    Sauvage M; Steckler T
    Neuroscience; 2001; 104(3):643-52. PubMed ID: 11440798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.
    Hall H; Reyes S; Landeck N; Bye C; Leanza G; Double K; Thompson L; Halliday G; Kirik D
    Brain; 2014 Sep; 137(Pt 9):2493-508. PubMed ID: 25062696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia.
    Dringenberg HC
    Behav Brain Res; 2000 Nov; 115(2):235-49. PubMed ID: 11000423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.
    Kuhl DE; Minoshima S; Fessler JA; Frey KA; Foster NL; Ficaro EP; Wieland DM; Koeppe RA
    Ann Neurol; 1996 Sep; 40(3):399-410. PubMed ID: 8797529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurochemical basis of dementia in Parkinson's disease.
    Hornykiewicz O; Kish SJ
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):185-90. PubMed ID: 6143610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease.
    Wenk GL; McGann K; Hauss-Wegrzyniak B; Rosi S
    Neuroscience; 2003; 121(3):719-29. PubMed ID: 14568031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced retrograde labelling with fluorescent tracer accompanies neuronal atrophy of basal forebrain cholinergic neurons in aged rats.
    De Lacalle S; Cooper JD; Svendsen CN; Dunnett SB; Sofroniew MV
    Neuroscience; 1996 Nov; 75(1):19-27. PubMed ID: 8923519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.